In addition, the anti-dengue EDI mAb does not interfere with the binding of anti-dengue IgG or anti-dengue IgM to the EDII and EDIII domains, which are the major binding sites of immunoglobulins produced against DENV in patients. This evidence concerns the gene TNRC6A and dengue disease.